Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Regulus Therapeutics, a biotech firm developing oligonucleotide drugs that target microRNAs, will cut 60% of its workforce, or about 35 jobs. The decision follows the observation of acute mouse toxicity in a Phase I study of RGLS4326, a treatment for autosomal dominant polycystic kidney disease. The firm also halted recruitment for a study of a microRNA drug it is developing with Sanofi.
This article has been sent to the following recipient: